Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $131.86

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received a consensus rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $131.86.

Several research analysts recently weighed in on LNTH shares. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reissued a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company.

Lantheus Price Performance

LNTH opened at $91.47 on Tuesday. The company has a 50 day simple moving average of $89.87 and a two-hundred day simple moving average of $100.22. The firm has a market cap of $6.36 billion, a P/E ratio of 15.22 and a beta of 0.46. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently modified their holdings of LNTH. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus in the third quarter valued at $1,066,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus in the 3rd quarter worth about $25,955,000. Van ECK Associates Corp boosted its stake in shares of Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after purchasing an additional 21,604 shares during the period. Finally, Swedbank AB grew its stake in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after buying an additional 125,843 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.